← All trials
NCT06958198
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 15, 2025
- Primary completion
- Oct 31, 2026
- Completion date
- Oct 31, 2026
- First posted
- May 6, 2025
- Last posted
- Nov 18, 2025
- Enrollment
- 56
- Arms / groups
- 6 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of OxfordLead sponsor
- Wellcome TrustCollaborator
- European and Developing Countries Clinical Trials Partnership (EDCTP)Collaborator
- Institut et Haute école de la Santé, La SourceCollaborator
- Government of GermanyCollaborator
- European Vaccine Initiative (EVI), Heidelberg, GermanyCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.